INTRODUCTION {#s1}
============

Lung cancer is a serious health problem in the whole world for many decades with its highest mortality \[[@R1]\]. It is histologically consisted of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for about 85% of the total cases. Platinum-based chemotherapy is the standard chemotherapy for first line treatment of NSCLC, especially for advance stage patients \[[@R2], [@R3]\]. However, the response to platinum-based chemotherapy is greatly variable among individuals, and drug resistance is easily occurred by intrinsic or acquired.

A number of studies suggested single nucleotide polymorphisms (SNPs) may affect chemotherapy response \[[@R4]--[@R9]\]. Most of the studies focused on the SNPs of genes in DNA repair pathways or transporters, such as ERCC1, XPD, XRCC1 and MDR1 \[[@R10]--[@R18]\]. However, inconsistent results came from different studies on the same issue. For example, Huang et al. and Zhao et al. reported that ERCC1 C8092A may be useful predictive markers for response to platinum-based chemotherapy \[[@R19], [@R20]\], but some other studies showed the contradictory results [@R21]--[@R23]\]. The same situations were also existed in MDR1 C3435T, XPD A2251C and other SNPs. Although several reviews and meta-analyses summarized the pharmacogenomics of platinum-based chemotherapy response in NSCLC patients \[[@R24]\], they still not reached the consistent conclusion. Moreover, the published meta-analyses were not comprehensive as they usually analyzed only one or several SNPs in their studies \[[@R25], [@R26]\].

In this study, we investigated the relationships between widely studied SNPs and platinum-based chemotherapy response in a larger NSCLC sample size. We also provided a comprehensive meta-analysis on pharmacogenomics of the platinum-based chemotherapy response. Understanding the genetic variants contributed to platinum-based chemotherapy will provide guide for individualized chemotherapy and benefit for NSCLC patients.

MATERIALS AND METHODS {#s2}
=====================

Subjects {#s2_1}
--------

A total of 1024 NSCLC patients were enrolled in our genotyping study. They were from Shanghai Chest, Shanghai Zhongshan, or Shanghai Changhai Hospitals (Shanghai, China) from 2005 to 2010, and Affiliated Cancer Hospital or Xiangya Hospital of Central South University (Changsha, Hunan, China) from 2011 to 2015 (Table [1](#T1){ref-type="table"}). The patients to be eligible for the study had to meet the following criteria: (1) histologically or cytologically confirmed NSCLC, and primary tumor in the lung; (2) Patients received platinum-based chemotherapy for at least two cycles, and had no surgery or radiotherapy before. Exclusion criteria included (1) pregnancy or lactation, (2) active infection, (3) symptomatic brain or leptomeningeal metastases, and (4) previous or concomitant other malignancies. Chemotherapy response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \[[@R27]\]. Responders were consisted of complete responders (CR) and partial responders (PR) while non-responders including stable disease (SD) and progressive disease (PD). All subjects provided written informed consent, incompliance with the code of ethics of the World Medical Association (Declaration of Helsinki) before this study. The study protocol was approved by the ethics committee of Xiangya School of Medicine, Central South University (registration number: CTXY-110008-2). We applied for clinical admission to the Chinese Clinical Trial Registry (registration number: ChiCTR-RO-12002873).

###### Clinical characteristics of responders and non-responders to platinum-based chemotherapy in NSCLC patients

  -----------------------------------------------------------------------------------------
  Characteristics             Responders (%) (*n* = 237)   Non-responders (%) (*n* = 787)
  --------------------------- ---------------------------- --------------------------------
  Sex\                        \                            \
  Male\                       174(73.4)\                   550(69.9))\
  Female                      63(26.6)                     237(30.1)

  Age\                        \                            \
  \<55\                       81(34.2)\                    310(39.4)\
  ≥55                         156(63.8)                    477(60.6)

  Smoking status\             \                            \
  Non-smoker\                 101(42.6)\                   354(45.0)\
  Smoker                      136(57.4)                    433(55.0)

  Stage\                      \                            \
  IIIa-IIIb\                  92(38.8)\                    241(30.6)\
  IV                          145(61.2)                    546(69.4)

  Histology\                  \                            \
  Squamous\                   145(61.2)\                   517(65.7)\
  Adenocarcinoma              92(38.8)                     270(34.3)

  Chemotherapeutic regimen\   \                            \
  Platinum/gemcitabine\       135(57.0)\                   357(45.4)\
  Platinum/paclitaxel\        55(23.2)\                    252(32.0)\
  Platinum/vinorelbine        47(19.8)                     178(22.6)
  -----------------------------------------------------------------------------------------

SNP selecting, DNA extracting and genotyping {#s2_2}
--------------------------------------------

By considering the meta-analysis of pharmacogenomics of platinum-based chemotherapy in NSCLC, we searched the publications which reported the associations of SNPs with platinum-based chemotherapy response of NSCLC in PubMed database, ISI Web of Knowledge and Cochrane Library. As shown in Figure [1](#F1){ref-type="fig"}, we found 13 SNPs were widely studied in different publications after systematic literature review. In order to get more reliable results by included more studies and with larger total sample size in the meta-analysis, we did genotyping study about these 13 SNPs in our samples. Information of the 13 SNPs was summarized in Table [2](#T2){ref-type="table"}.

![Flow chart of literature selection](oncotarget-07-55741-g001){#F1}

###### Polymorphisms involved in the study

  Pathways         Genes   Polymorphisms              References
  ---------------- ------- -------------------------- ---------------------------------------------------------------------------------------------------
  DNA repair       ERCC1   C354T (Asn118Asn)          [@R7],[@R10],[@R11],[@R14],[@R16],[@R17],[@R19]--[@R22],[@R41],[@R44],[@R46],[@R51],[@R67],[@R69]
                           C8092A (Gln504Lys)         [@R16],[@R17],[@R19]--[@R23],[@R47],[@R51]
  Detoxification   GSTP1   A313G (Ile105Val)          [@R7],[@R15],[@R38],[@R51],[@R65],[@R67]
  Transporter      MDR1    C3435T (Ile154Ile)         [@R10],[@R11],[@R13],[@R18],[@R39]
                           G2677T/A (Ala893Ser/Thr)   [@R10],[@R13],[@R18]
  DNA repair       XPD     A2251C (Lys751Gln)         [@R7],[@R11],[@R12],[@R21],[@R22],[@R35],[@R41]--[@R49],[@R51],[@R69]
                           G934A (Asp312Asn)          [@R7],[@R11],[@R12],[@R22],[@R43]--[@R45],[@R48],[@R49],[@R51],[@R69]
  DNA repair       XPG     G3310C (His1104Asp)        [@R8],[@R36],[@R38]
                           T138C (His46His)           [@R8],[@R9],[@R36],[@R38]
  DNA repair       XRCC1   G1196A (Arg399Gln)         [@R7],[@R15],[@R22],[@R36]--[@R38],[@R40],[@R46],[@R50]--[@R52]
                           C580T (Arg194Trp)          [@R35]--[@R38],[@R40],[@R52]
  DNA repair       XRCC3   C18067T (Lys27Gln)         [@R7],[@R22],[@R36],[@R41],[@R42],[@R52]
  Metabolism       CDA     A79C (Thr241Met)           [@R7],[@R41],[@R45],[@R69]

Genomic DNA of all subjects was isolated from a 5 mL peripheral blood sample using the FlexiGene DNA Kit (Qiagen, Hilden, Germany) and stored at −20C until use. Genotyping was conducted by the Sequenom MassARRAY system (Sequenom, San Diego, CA, USA).

Publication search and inclusion criteria {#s2_3}
-----------------------------------------

We did a systematic literature search in PubMed database, ISI Web of Knowledge and Cochrane Library. The identified articles were reviewed carefully to find more relevant articles. The included articles were published before November 23^th^ 2015. Keywords for searching the related publications were platinum (platinum, cisplatin, carboplatin, oxaliplatin) and polymorphism (polymorphism, SNP, mutation, variation, single nucleotide polymorphism) and lung cancer.

The inclusion criteria of publications were as follows: (1) studies about platinum-based chemotherapy response; (2) Patients with NSCLC; (3) the data of genotypes in responders and nonresponders could be obtained. Studies were excluded by any one of the following conditions: (1) the data of genotypes could not be provided; (2) articles involved in patients received surgery or radiotherapy.

Data extraction {#s2_4}
---------------

All data were extracted independently by two investigators (JC and ZW) using the same data recording form, but they were blind to each other during the whole extracting process. The discrepancies of the extracted data were discussed and resolved with consensus. The following information were collected from each study: first author\'s name, publication year, ethnicity, country, sample size, polymorphisms, alleles of the investigated polymorphism, genotyping methods, disease stage, chemotherapy regimen, and the numbers of responders and non-responders in different genotypes.

Statistical analysis {#s2_5}
--------------------

In our genotyping study, the chi-square and Student t tests were used to determine the differences in sex, age, smoking status and histology between responders and nonresponders. Unconditional logistic regression was performed to estimate the association of the polymorphisms with chemotherapy response by calculating odds ratios and their 95% confidence intervals with adjustments. The association study was analyzed in additive, dominant and recessive models. The *P* value was 2 sided, and *P* \< 0.05 was considered statistically significant. The aforementioned statistical analyses were performed by PLINK 1.07 \[[@R28]\] and SPSS 18.0 (IBM, Armonk, NY, USA).

In the meta-analysis, the pooled odds ratio (OR) and associated 95% confidence interval (95% CI) were calculated by using the Z test. The genetic model was chosen by logistic regression \[[@R29]\]. The heterogeneity of publications in each meta-analysis was assessed by using Q statistic test, it with a significance level of *P* \< 0.05. We selected the random-effect model to get the results with a wider CIs if *P* \< 0.05. Otherwise, the fixed-effect model was used to calculate the pooled ORs and *P* values \[[@R30], [@R31]\]. To further evaluate the extent of heterogeneity between publications, I^2^ statistic test was also employed, its values of 25%, 50% and 75%were considered as low, moderate and high heterogeneity respectively \[[@R32]\]. The publication bias was examined by the inverted funnel plots, Begg\'s test \[[@R33]\]and Egger\'s test \[[@R34]\]. All calculations were conducted by Stata 12.0 (StataCorp LP, College Station, USA). The *P* value was 2 sided, and *P* \< 0.05 was considered statistically significant.

RESULTS {#s3}
=======

Associations of the Polymorphisms with platinum-based chemotherapy response in genotyping study {#s3_1}
-----------------------------------------------------------------------------------------------

1024 NSCLC patients were enrolled in our genotyping study and their clinical characteristics were summarized in Table [1](#T1){ref-type="table"}. All of the patients received platinum-based chemotherapy at least two cycles. 237 of them showed good response while 787 had poor response to the treatment. 13 SNPs attempted to be genotyped by Sequenom\'s MassARRAY system, but 3 (XRCC1 C580T, CDA A79C, XRCC3 C18067T) of the SNPs were failed in primer design since primers of these 3 SNPs would form heterodimers with other primers. Additionally, 2 SNPs (MDR1 G2677T/A, XPD G934A) were not genotyped successfully in all samples, their genotyping results failed in Hardy-Weinberg equilibrium test. The results of associations between 8 SNPs and platinum-based chemotherapy were shown in Table [3](#T3){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"}. XRCC1 G1196A was significantly related to the platinum-based chemotherapy response. Patients with GA or GG genotypes were more sensitive to platinum-based chemotherapy. We also conducted subgroup analyses which samples selected by age (55 years old), sex, smoking status, histology or chemotherapy regimen. The results of subgroup analyses were summarized in Table [4](#T4){ref-type="table"}. In patients with \<55 years old, GSTP1 A313G and XPG G3310C were related to the chemotherapy response. In patients with ≥55 years old, ERCC1 C354T was associated with chemotherapy response. MDR1 C3435T, G2677T/A and XPD A2251C showed significant associations in patients of females. XRCC1 G1196A was related to drug response in smoking patients. In AC subgroup, ERCC1 C354T and XPG T138C were associated with platinum sensitivity. In patients with VP treatment, XRCC1 G1196A and MDR1 C3435T were correlated with platinum-based chemotherapy response.

###### Association of XRCC1 G1196A with platinum-based chemotherapy response in our genotyping study

  Gene    Polymorphisms   Genotype   Responders   Non-responders   Additive          Dominant   Recessive                                                                      
  ------- --------------- ---------- ------------ ---------------- ----------------- ---------- ----------------- ------------------------------------------ ----------------- -------
  XRCC1   G1196A          GG         104(43.9)    400(50.8)        0.80(0.63-1.02)   0.072      0.72(0.53-0.96)   0.028[\*](#tfn_001){ref-type="table-fn"}   0.99(0.54-1.80)   0.968
                          GA         110(46.4)    292(37.1)                                                                                                                    
                          AA         15(6.3)      47(6.0)                                                                                                                      

*P* \< 0.05

###### Stratification analyses of the associations of polymorphisms and platinum-based chemotherapy response in our genotyping study

  Gene    Polymorphisms   Subgroups   Additive           Dominant                                   Recessive                                                                        
  ------- --------------- ----------- ------------------ ------------------------------------------ ------------------ ------------------------------------------ ------------------ ------------------------------------------
  GSTP1   rs1695          \<55        2.03(1.18-3.46)    0.010[\*](#tfn_002){ref-type="table-fn"}   2.36(1.29-4.28)    0.005[\*](#tfn_002){ref-type="table-fn"}   1.49(0.32-6.88)    0.607
  XPG     rs17655         \<55        0.68(0.47-0.98)    0.038[\*](#tfn_002){ref-type="table-fn"}   0.44(0.23-0.86)    0.016[\*](#tfn_002){ref-type="table-fn"}   0.76(0.43-1.35)    0.348
  ERCC1   rs11615         ≥55         1.65(1.15-2.36)    0.006[\*](#tfn_002){ref-type="table-fn"}   1.59(1.05-2.41)    0.028[\*](#tfn_002){ref-type="table-fn"}   5.13(1.20-21.98)   0.028[\*](#tfn_002){ref-type="table-fn"}
  XPD     rs13181         Females     4.95(1.08-22.72)   0.040[\*](#tfn_002){ref-type="table-fn"}   4.95(1.08-22.72)   0.040[\*](#tfn_002){ref-type="table-fn"}                      
  MDR1    rs1045642       Females     0.67(0.46-0.99)    0.048[\*](#tfn_002){ref-type="table-fn"}   0.55(0.30-1.00)    0.052                                      0.63(0.31-1.27)    0.194
  MDR1    rs2032582       Females     1.43(0.98-2.09)    0.065                                      1.27(0.68-2.37)    0.453                                      2.44(1.17-5.05)    0.017[\*](#tfn_002){ref-type="table-fn"}
  XRCC1   rs25487         Smokers     0.74(0.53-1.02)    0.063                                      0.64(0.43-0.94)    0.024[\*](#tfn_002){ref-type="table-fn"}   1.01(0.56-1.81)    0.945
  ERCC1   rs11615         AC          1.85(1.17-2.92)    0.009[\*](#tfn_002){ref-type="table-fn"}   2.05(1.18-3.58)    0.011[\*](#tfn_002){ref-type="table-fn"}   2.73(0.79-9.40)    0.112
  XPG     rs1047768       AC          0.53(0.36-0.77)    0.001[\*](#tfn_002){ref-type="table-fn"}   0.52(0.32-0.86)    0.010[\*](#tfn_002){ref-type="table-fn"}   0.30(0.13-0.65)    0.003[\*](#tfn_002){ref-type="table-fn"}
  XRCC1   rs25487         VP          0.62(041-1.15)     0.148                                      0.49(0.25-0.95)    0.035[\*](#tfn_002){ref-type="table-fn"}   1.71(0.36-8.07)    0.496
  MDR1    rs1045642       VP          0.62(0.39-0.99)    0.047[\*](#tfn_002){ref-type="table-fn"}   0.70(0.35-1.42)    0.325                                      0.34(0.15-0.78)    0.011[\*](#tfn_002){ref-type="table-fn"}

NSCLC: Non-Small Cell Lung Cancer; VP: Navelbine /Platinum; AC: Adenocarcinoma

*P* \< 0.05

Results of meta-analysis {#s3_2}
------------------------

### Characteristics of eligible studies {#s3_2_1}

Overall 4014 studies were selected during the first step of systematic literature review about platinum and lung cancer. With further reviewed, there were 475 studies were involved in single nucleotide polymorphisms. After reviewing the abstracts, 32 reviews or meta-analyses and 306 irrelevant studies were excluded. After reading the full texts of the 137 articles which left for reviewed in next step, we found that 41 articles focused on prognosis or toxicity of platinum-based chemotherapy, 21 lacked enough information, 19 were *in vitro* studies, 9 were about small cell lung cancer, 7 involved in patients with surgery or radiotherapy, and 1 was duplicated publication. Finally, there were 39 publications and our genotyping study included in meta-analysis. The publications included 13 SNPs in 8 genes (Figure [1](#F1){ref-type="fig"}). The characteristics of these studies were summarized in Table [5](#T5){ref-type="table"}. Funnel plot, Begg\'s test and Egger\'s test were used to estimate publication bias among the included studies. Visual inspection of the funnel plot of SNPs revealed a symmetrical inverted V shape ([Figure S1](#SD1){ref-type="supplementary-material"}).

###### Characteristics of eligible publications considered in the meta-analysis

  Authors            Year   Ethnicity(Country)           Number of patients   Disease stage   Chemotherapy regimans          Genotyping methods                            Genes and polymorphisms                                                            Reference number
  ------------------ ------ ---------------------------- -------------------- --------------- ------------------------------ --------------------------------------------- ---------------------------------------------------------------------------------- ------------------
  Ryu et al.         2003   Asian (Korea)                109                  IIIB-IV         cisplatin-based chemotherapy   SNaPShot assay                                ERCC1 C354T,XPD A2251C,XPD G934A                                                   [@R44]
  Isla et al.        2004   Caucasian (Spain)            62                   IIIB-IV         cisplatin-docetaxel            TaqMan                                        ERCC1 C354T,XPD A2251C,XPD G934A,MDR1 C3435T                                       [@R11]
  Yuan et al.        2005   Asian (China)                151                  IIIB-IV         platinum-based chemotherapy    PCR-RFLP                                      XPD A2251C, ERCC1 C8092A                                                           [@R47]
  Booten et al.      2006   Caucasian (United Kingdom)   89                   III-IV          platinum-based chemotherapy    Direct sequencing                             GSTP1 A313G                                                                        [@R65]
  Yuan et al.        2006   Asian (China)                200                  IIIB-IV         platinum-based chemotherapy    PCR-RFLP                                      XPD A2251C, XRCC1 C580T                                                            [@R35]
  Booton et al.      2006   Caucasian (United Kingdom)   89                   III-IV          platinum-based chemotherapy    PCR-RFLP                                      XPD A2251C,XPD G934A                                                               [@R12]
  Pan et al.         2008   Asian (China)                69                   IIIB-IV         cisplatin-vinorelbine          PCR-RFLP                                      MDR1 C3435T,MDR1 G2677T                                                            [@R18]
  Sun et al.         2008   Asian (China)                87                   IV              platinum-based chemotherapy    3D polyacrylamide gel-based DNA microarray    XPG G3310C,XPG T138C,XRCC1 G1196A,XRCC1 C580T                                      [@R38]
  Tibaldi et al.     2008   Caucasian (Italy)            65                   IIIB-IV         cisplatin-gemcitabine          Taqman probe--based assays                    ERCC1 C354T, XPD A2251C,XPD G934A,CDA A79C                                         [@R69]
  Hong et al.        2009   Asian (China)                164                  III-IV          cisplatin-vinorelbine          PCR-RFLP                                      XRCC1 G1196A,XRCC1 C580T                                                           [@R40]
  Kalikaki et al.    2009   Caucasian (Greece)           119                  IIIA-IV         platinum-based chemotherapy    PCR-RFLP Direct sequencing                    ERCC1 C354T,ERCC1 C8092A,XPD A2251C,XPD G934A,XRCC1 G1196A,GSTP1 A313G             [@R51]
  Pan et al.         2009   Asian (China)                54                   IIIB-IV         cisplatin-docetaxel            PCR-RFLP                                      MDR1 C3435T, MDR1 G2677T                                                           [@R13]
  Sun et al.         2009   Asian (China)                113                  IIIA-IV         platinum-based chemotherapy    3-D polyacrylamide gel-based DNA microarray   GSTP1 A313G                                                                        [@R38]
  Feng et al.        2009   Asian (China)                115                  III-IV          platinum-based chemotherapy    Gelbased DNA microarray                       XPG T138C                                                                          [@R9]
  Chen et al.        2010   Asian (China)                95                   IIIB-IV         cisplatin-based chemotherapy   ligase detection reactions                    ERCC1 C354T,MDR1 C3435T,MDR1 G2677T                                                [@R10]
  Li F et al.        2010   Asian (China)                115                  IIIB-IV         platinum-based chemotherapy    3-D polyacrylamide gel-based DNA microarray   ERCC1 C354T,ERCC1 C8092A,XPD A2251C                                                [@R21]
  Wang et al.        2010   Asian (China)                90                   IIIB-IV         cisplatin-based chemotherapy   Direct sequencing                             ERCC1 C354T,ERCC1 C8092A                                                           [@R16]
  Joerger et al.     2011   Caucasian (Netherlands)      137                  IIIB-IV         platinum-gemcitabine           DNA sequencing                                ERCC1 C354T,XPD A2251C,XPD G934A,XRCC1 G1196A,XRCC3 C18067T,GSTP1 A313G,CDA A79C   [@R7]
  KimCurran et al.   2011   Asian (China)                300                  IIIB-IV         cisplatin-based chemotherapy   RT-PCR                                        ERCC1 C8092A                                                                       [@R23]
  Ludovini et al.    2011   Caucasian (Italy)            192                  IIIB-IV         cisplatin-based chemotherapy   Taqman                                        ERCC1 C354T,XPD A2251C,CDA A79C,XRCC3 Thr241Met                                    [@R41]
  Zhou et al.        2011   Asian (China)                111                  IV              platinum-based chemotherapy    PCR-RFLP                                      GSTP1 A313G,XRCC1 G1196A                                                           [@R52]
  Xu et al.          2011   Asian (China)                130                  IIIB-IV         platinum-based chemotherapy    PCR-RFLP                                      XRCC1 rs25487 G1196A,XRCC1 rs1799782 C580T,XRCC3 C18067T                           [@R39]
  Yan et al.         2011   Asian (China)                103                  IIIB-IV         platinum-based chemotherapy    RT-PCR                                        MDR1 C3435T                                                                        [@R15]
  Li D et al.        2012   Asian (China)                89                   IIIA-IV         cisplatin-based chemotherapy   Gene sequencing analysis technique            ERCC1 C354T,XPD A2251C,XRCC1 G1196A                                                [@R46]
  Krawczyk et al.    2012   Caucasian (Poland)           43                   IIIB-IV         platinum-based chemotherapy    PCR-RFLP                                      ERCC1 C354T                                                                        [@R14]
  Liao et al.        2012   Asian (China)                62                   IIIB-IV         cisplatin-based chemotherapy   SNPstream UHT                                 ERCC1 C354T,ERCC1 C8092A,XPD A2251C,XPD G934A,XRCC1 G1196A,XRCC3 C18067T           [@R22]
  Wu et al.          2012   Asian (China)                353                  IIIA-IV         platinum-based chemotherapy    Sequenom MassARRAY                            XPD A2251C,XPD G934A                                                               [@R49]
  Chen et al.        2012   Asian (China)                256                  IIIB-IV         platinum-based chemotherapy    PCR-RFLP                                      XPD A2251C, XRCC3 C18067T                                                          [@R42]
  Hong et al.        2013   Asian (China)                135                  IIIB-IV         platinum-based chemotherapy    TaqMan assays                                 ERCC1 C354T,ERCC1 C8092A                                                           [@R17]
  Huang et al.       2013   Asian (China)                187                  IIIA-IV         platinum-based chemotherapy    MassARRAY                                     ERCC1 C354T,ERCC1 C8092A                                                           [@R19]
  Li X et al.        2013   Asian (China)                496                  IIIA-IV         platinum-based chemotherapy    Sequenom MassARRAY                            XPD A2251C,XPD G934A                                                               [@R48]
  Zhang et al.       2013   Asian (China)                451                  IIIA-IV         platinum-based chemotherapy    TaqMan                                        XPG G3310C,XPG T138C                                                               [@R8]
  Lv et al.          2014   Asian (China)                91                   IIIB-IV         cisplatin-based chemotherapy   TaqMan-MGB                                    ERCC1 C354T,GSTP1 A313G                                                            [@R67]
  Peng et al.        2014   Asian (China)                235                  IIIA-IV         cisplatin-based chemotherapy   PCR-RFLP                                      XRCC1 G1196A                                                                       [@R50]
  Zhang et al.       2014   Asian (China)                375                  IIIA-IV         platinum-based chemotherapy    Sequenom MassARRAY                            XRCC1 G1196A,XRCC1 C580T                                                           [@R37]
  Zhao et al.        2014   Asian (China)                162                  IIIA-IV         platinum-based chemotherapy    MassARRAY                                     ERCC1 C354T, ERCC1 C8092A                                                          [@R20]
  Zhou et al.        2014   Asian (China)                93                   IIIB-IV         cisplatin-based chemotherapy   PCR-RFLP                                      XPD A2251C,XPD G934A,CDA A79C                                                      [@R45]
  Jin et al.         2014   Asain(China)                 378                  I-IV            cisplatin-based chemotherapy   PCR-RFLP                                      XPG G3310C,XPG T138C,XRCC1 G1196A,XRCC1 C580T,XRCC3 C18067T                        [@R36]
  Li P et al.        2015   Asian (China)                142                  IIIB-IV         cisplatin-Vinorelbine          PCR-RFLP                                      XPD A2251C,XPD G934A                                                               [@R43]

### Pooled analysis of chemotherapy response {#s3_2_2}

The pooled estimate results of the 13 SNPs were shown in Figure [2](#F2){ref-type="fig"} and [Figure S2](#SD1){ref-type="supplementary-material"}. 6 studies examined the association of XRCC1 C580T with platinum sensitivity in NSCLC patients \[[@R35]--[@R40]\]. It included 1343 subjects which 650 carried CC genotype and 693 with CT+TT genotype. We chose random-effect model since there was heterogeneity across the studies (*P* = 0.026, I^2^ = 61.3%). Pooled data showed there was significant relationship between XRCC1 C580T and drug response (OR = 0.54, 95%CI: 0.37-0.80, *P* = 0.002) (Figure [2A](#F2){ref-type="fig"}). Patients of XRCC1 C580T CT and TT carriers had better response than CC carriers. Meta-analysis of XRCC3 C18067T included 6 studies \[[@R7], [@R22], [@R36], [@R39], [@R41], [@R42]\]. There was no heterogeneity across these studies (*P* = 0.427, I^2^ = 0%), thus we chose fixed-effect model. Pooled data contained 1234 NSCLC patients, 408 were responders and 826 were non-responders. The pooled estimated result showed that this polymorphism was significantly correlated with chemotherapy response (OR = 0.69, 95%CI: 0.52-0.91, *P* = 0.009) (Figure [2B](#F2){ref-type="fig"}). XRCC3 C18067T CT and TT genotypes carriers showed better drug response. However, no significant associations were found between the other polymorphisms and chemotherapy response ([Figure S2](#SD1){ref-type="supplementary-material"}).

![Meta-analysis of associations of XRCC1 C580T and XRCC3 C18067T with platinum-based chemotherapy response in NSCLC patients](oncotarget-07-55741-g002){#F2}

### Stratified analyses of chemotherapy response {#s3_2_3}

Since moderate or high heterogeneity was showed in pooled analysis of several SNPs, and for considering that ethnic differences and different chemotherapy regimen may contribute to the drug response, we conducted stratified analyses of Asian, Caucasian and cisplatin-based chemotherapy. It was interesting to found that XPD A2251C was significantly correlated with platinum response in Asian population by pooling 12 studies \[[@R7], [@R21], [@R22], [@R35], [@R42]--[@R49]\] included 2570 subjects (OR = 1.29, 95%CI: 1.03-1.62, *P* = 0.026) (Figure [3A](#F3){ref-type="fig"}). Patients of Asians with XPD A2251C AA genotype could be more sensitive to platinum-based chemotherapy. XRCC3 C18067T was significantly related to drug response in Caucasian population (OR = 0.50, 95%CI: 0.30-0.85, *P* = 0.011) (Figure [3B](#F3){ref-type="fig"}). Patients of Caucasians with CT and TT genotypes of this polymorphism had better drug response. By only pooling the investigations that patients received cisplatin-based chemotherapy, MDR1 C3435T and MDR1 G2677T/A were significantly correlated to chemotherapy response (OR = 1.90, 95%CI: 1.14-3.17, *P* = 0.013; OR = 2.36, 95%CI: 1.30-4.29, *P =* 0.005, respectively) (Figure [3C and 3D](#F3){ref-type="fig"}). Patients carrying CC genotype of MDR1 C3435T or GG genotype of MDR1 G2677T/A had better chemotherapy response. There were 11 publications studied association of XRCC1 G1196A \[[@R7], [@R22], [@R36]--[@R40], [@R46], [@R50]--[@R52]\], but high heterogeneity (*P*\<0.001, I^2^ = 74.3%) and publication bias exist among the studies (Begg\'s test *P* = 0.024; Egger\'s test *P =* 0.002). Moreover, it was hardy to determine about the association of XPD A2251C with chemotherapy response for its 95%CI was 0.99-1.44. Thus, we made quality assessment about the publications by using quality scoring criteria from Wu\'s study \[[@R26]\], but it was modified by considering high (or low) quality if the score \>12 (or ≤12) in our analyses. We did quality stratified analyses in SNPs which reported in more than 10 studies. The results showed that XPD A2251C was more likely related to drug response in pooled analysis of high quality publications which included 2625 patients (OR = 1.22, 95%CI: 1.00-1.50, *P* = 0.05) (Figure [4A](#F4){ref-type="fig"}), and XRCC1 G1196A was associated with chemotherapy response in high quality publications with low heterogeneity. (OR = 0.74, 95%CI: 0.62-0.89, *P* = 0.001) (Figure [4B](#F4){ref-type="fig"}).

![Meta-analysis of association polymorphisms of chemotherapy response in different subgroups](oncotarget-07-55741-g003){#F3}

![Meta-analysis of association polymorphisms of chemotherapy response after quality assessment of studies](oncotarget-07-55741-g004){#F4}

### Quality assessment of meta-analysis results {#s3_2_4}

The reliability of our meta-analysis results were assessed by the criteria described in [Table S2](#SD1){ref-type="supplementary-material"}. Score was determined by the following 4 factors: number of included publications, sample size of patients, heterogeneity and publication bias. Total score ranged from 2 to 12. Meta-analysis results were considered low or medium or high reliability if the score were 2-6 or 7-9 or 10-12. The quality assessment results were described in Table [6](#T6){ref-type="table"}. We were exciting to notice that high reliability showed about XRCC1 G1196A pooled analysis result in high quality studies, while the total pooled analysis result was in low reliability. Moreover, our genotyping study result of XRCC1 G1196A was consistent with the high reliability result.

###### Quality assessment of meta-analysis results

  Genes   SNPs       Total pooled analysis reliability (score)   Subgroup analysis reliability (score)                                          
  ------- ---------- ------------------------------------------- --------------------------------------- ------------ ------------ ------------ ------------
  ERCC1   C354T      High (10)                                   High (10)                               Medium (7)   Medium (9)   Medium (7)   Medium (8)
          C8092A     High (11)                                   Medium (9)                              Medium (8)   Medium (9)                Medium (8)
  GSTP1   A313G      Medium (8)                                                                                       Low (6)      Medium (8)   
  MDR1    C3435T     Medium (9)                                                                                       Medium (8)                Medium (8)
          G2677T/A   Medium (7)                                                                                                                 Medium (8)
  XPD     A2251C     High (12)                                   High (12)                               Medium (8)   High (12)    Medium (9)   Medium (9)
          G934A      High (12)                                   Medium (9)                              Medium (8)   Medium (9)   Medium (8)   Medium (7)
  XPG     G3310C     Medium (9)                                                                                                                 
          T138C      Medium (7)                                                                                                                 
  XRCC1   G1196A     Low (6)                                     High (10)                               Medium (8)   Medium (9)   Medium (8)   
          C580T      Medium (8)                                                                                                                 
  CDA     A79C       Medium (7)                                                                                                    Medium (7)   Low (6)
  XRCC3   C18067T    High (10)                                                                                        Medium (8)   Medium (8)   

DISCUSSION {#s4}
==========

In this study, we investigated the associations of widely studied SNPs (13 polymorphisms in 8 genes) with platinum-based chemotherapy response in NSCLC patients. We also conducted a comprehensive meta-analysis of these SNPs. Our results showed that XRCC1 G1196A/C580T, and XRCC3 C18067T were significantly correlated with platinum-based chemotherapy. XPD A2251C, MDR1 C3435T and MDR1 G2677T/A, GSTP1 A313G, XPG G3310C, ERCC1 C354T were correlated to platinum-based chemotherapy response in different subgroups.

Platinum-based chemotherapy was widely used for treatment of advanced NSCLC, but pharmacogenomic differences between individuals may affect drug response. In the last several decades, gene polymorphisms were revealed to play an important role in chemotherapy response \[[@R24]\]. Therefore, most studies focused on the polymorphisms of genes involved in DNA repair pathway, transporters, metabolism and detoxification. In this study, we selected 9 SNPs in DNA repair pathway genes, 2 SNPs of transporter genes and 2 from metabolism and detoxification genes. They were extensively studied by researchers but results were not consistent. We used a larger sample size (n = 1024) to detect relationships between these SNPs and platinum-based chemotherapy response in NSCLC. Moreover, we conducted a meta-analysis to verify the results.

DNA repair was one of the classical platinum resistance mechanism \[[@R53]\]. Polymorphisms in genes of DNA repair pathway could affect DNA repair capacity and alter sensitivity to platinum-based chemotherapy. In this study, XRCC1 G1196A was significantly correlated to platinum-based chemotherapy response both in our genotyping study and meta-analysis. XRCC1 C580T and XRCC3 C18067T were also related to the drug response from the meta-analysis. XRCC1 and XRCC3 were both DNA base excision repair (NER) genes. XRCC1 G1196A/C580T and XRCC3 C18067T were all non-synonymous SNPs. They could directly contribute to gene expression and activity. Increased NER capacity would lead to decrease sensitivity of patients to chemotherapy \[[@R54]\]. A recent meta-analysis conducted by Gao et.al \[[@R55]\] about XRCC1 G1196A and C580T showed consistent result with our findings about XRCC1 C580T, but no significantly association showed about XRCC1 G1196A in their study. We carefully compared the included studies in the two meta-analyses. Most of studies included in their meta-analysis were small sample size studies, and they also included the studies with patients received radiotherapy which we excluded \[[@R56], [@R57]\]. For DNA repair gene polymorphisms, additionally, we also found that XRCC3 C18067T showed contribution to drug response in Caucasians and XPD A2251C was related to the response in Asian population. Allele frequency usually different between races, and racial differences were important factors for drug response \[[@R58], [@R59]\]. We did not find any statistical evidence for associations between the other SNPs (ERCC1 C354T/C8092A, XPD G934A and XPG G3310C/T138C) in DNA repair pathway and drug response in the meta-analysis. In our genotyping study, these polymorphisms also showed no significant correlations to platinum-based chemotherapy response in the overall analysis.

Transporters involved in drug resistance by decrease uptake or efflux of the drugs by the proteins known as ATP binding cassette transporters \[[@R60]\]. MDR1 also named ABCB1, it encodes P-glycoprotein which is an ATP-dependent drug efflux. It is responsible for decreased drug accumulation and often mediates the development of resistance to anticancer drug \[[@R61]--[@R63]\]. We found that both MDR1 C3435T and G2677T/A were associated with cisplatin-based chemotherapy response from the results of meta-analysis. However, the numbers of subjects pooled for these two SNPs in cisplatin-based chemotherapy subgroup were small. We considered that these associations maybe need further investigations. Additionally, there were several findings in our genotyping study about the SNPs. Both MDR1 C3535T and G2766T/A were associated with platinum-based chemotherapy response in females, and MDR1 C3435T also related to platinum response in AC patients.

GSPT1 and CDA were metabolism and detoxification pathway genes. GSTP1 was a member of GST family. It mediates formation of platinum-glutathione adduct \[[@R64]\] which decreased chemotherapy sensitivity. 7 studies were included in GSTP1 A313G pool analysis \[[@R51], [@R52], [@R65]--[@R67]\], but no significant correlation between this polymorphism and chemotherapy response. However, we found GSTP1 A313G related to platinum-based chemotherapy response of patients with \<55 year old in our genotyping study. CDA is an enzyme that metabolic inactivation of gemcitabine \[[@R68]\]. The patients in 4 studies of CDA A79C were received platinum-gemcitabine treatment \[[@R7], [@R41], [@R45], [@R69]\], but no associations were found in the meat-analysis of CDA A79C.

We conducted this study to get comprehensive conclusions about SNPs contributed to platinum-based chemotherapy response in NSCLC patients, but there were several possible limitations. It was unfortunately about the genotyping of XRCC1 C580T and XRCC3 C18067T failed in our samples, thus meta-analyses of these two SNPs were calculated without the results from our genotyping study. In meta-analyses of ERCC1 and MDR1, we did not include the data from the studies by Krawczyk et al. \[[@R70]\] and Du et al. \[[@R71]\] because they classified SD patients as responders. Our meta-analysis mainly used unadjusted estimates because not all publications presented their adjusted estimates. Finally, we attempted to conduct meta-analysis in each subgroup, but the other publications did not conduct subgroup analysis, or when they did but not in the same way. Thus, we cannot do pool analyses in the subgroups.

It was our first attempt to evaluate the quality of meta-analysis results. Only ERCC1 C3435T/C8092A, XPD A2251C/G934A, XRCC1 G1196A and XRCC3 C18067T showed high reliability. It means the other SNPs may need more investigations, though most of them showed medium reliability. In conclusion, contributions of XRCC1 G1196A/C580T and XRCC3 C18067T to drug response were further confirmed by our large sample size genotyping study and comprehensive meta-analysis. It is meaningful for personalized platinum-based treatment of NSCLC.
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